TWO · 1780.TWO
Allied Biotech Corporation
NT$23.95-NT$0.10 (-0.42%)
Allied Biotech Corporation’s quoted price sits in the lower half of its reported 52-week range, 35.01% below the high.
Loading market information…
TWO · 4127.TWO · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Tien Liang BioTech Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 63.7% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Tien Liang BioTech Co., Ltd.’s forward annual dividend is NT$0.30 per share, paid annual. The forward yield is 0.86% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Tien Liang BioTech Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Tien Liang BioTech Co., Ltd., established in 1960 and headquartered in New Taipei City, Taiwan, is a pharmaceutical enterprise involved in the development, manufacturing, and global distribution of a diverse array of health and medicinal products. The company's offerings include traditional Chinese medicine (TCM) formulations, predominantly in pill form. These remedies address a broad spectrum of conditions, such as internal organ deficiencies (e.g., liver and kidney), various forms of musculoskeletal and neuropathic discomfort (including low back pain, joint pain, rheumatism, gout, and neuralgia), and common ailments like dizziness, digestive issues (constipation, hemorrhoids), respiratory symptoms (colds, bronchitis, coughs), and skin conditions (athlete's foot). Additionally, Tien Liang BioTech provides a range of Western pharmaceutical products. This segment features topical applications like ointments, pain relief gels, soreness sprays, and transdermal pain patches, alongside oral preparations such as tablets and capsules. The portfolio also includes specialized items like hair removal creams. Beyond pharmaceuticals, the company extends its reach into general consumer health and personal care. These offerings comprise products designed for body relaxation and comfort, items to alleviate post-exercise discomfort, oral hygiene products, and various soaps.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$23.95-NT$0.10 (-0.42%)
Allied Biotech Corporation’s quoted price sits in the lower half of its reported 52-week range, 35.01% below the high.
NT$18.70-NT$0.15 (-0.8%)
NaviFUS Corp.’s quoted price sits in the lower half of its reported 52-week range, 30.87% below the high.
NT$21.20+NT$0.20 (+0.95%)
Bioptik Technology Incorporation’s quoted price sits in the lower half of its reported 52-week range, 24.29% below the high.
NT$32.15+NT$0.45 (+1.42%)
Lagis Enterprise Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.57% below the high.
NT$19.70-NT$0.60 (-2.96%)
Anxo Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.57% below the high.
NT$23.20-NT$0.50 (-2.11%)
Excelsior Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.06% below the high.
NT$14.90-NT$0.40 (-2.61%)
Enimmune corporation’s quoted price sits in the lower half of its reported 52-week range, 33.92% below the high.
NT$27.15-NT$1.35 (-4.74%)
Prince Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 19.67% below the high.
